

Jin-Hee Ahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9572477/publications.pdf>

Version: 2024-02-01

90
papers

1,453
citations

394421

19
h-index

361022

35
g-index

94
all docs

94
docs citations

94
times ranked

2935
citing authors

#	ARTICLE	IF	CITATIONS
1	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. <i>Lancet Oncology</i> , The, 2016, 17, 1261-1271.	10.7	161
2	How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. <i>ESMO Open</i> , 2018, 3, e000357.	4.5	112
3	Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. <i>American Journal of Clinical Pathology</i> , 2015, 144, 278-288.	0.7	103
4	Diagnostic accuracy and safety of ^{18}F -fluoro- $^{17}\beta$ -oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 546-555.	10.7	85
5	Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. <i>Oncotarget</i> , 2016, 7, 30119-30132.	1.8	62
6	Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab. <i>American Journal of Clinical Pathology</i> , 2015, 144, 570-578.	0.7	52
7	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , 2016, 7, 10547-10556.	1.8	52
8	A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. <i>International Journal of Cancer</i> , 2018, 143, 3240-3247.	5.1	46
9	Expression of <i>FOXM1</i> and related proteins in breast cancer molecular subtypes. <i>International Journal of Experimental Pathology</i> , 2016, 97, 170-177.	1.3	43
10	Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane. <i>Journal of Korean Medical Science</i> , 2004, 19, 547.	2.5	40
11	A Randomized Feasibility Study of ^{18}F -Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 563-568.	5.0	40
12	Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01). <i>Cancer Research and Treatment</i> , 2019, 51, 43-52.	3.0	34
13	Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients. <i>Breast</i> , 2016, 28, 67-72.	2.2	33
14	Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 104-110.	2.3	28
15	Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e297-e304.	1.9	28
16	High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 701-709.	2.8	25
17	Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 385-393.	2.8	23
18	Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with <i>MET</i> -amplified gastric cancer. <i>Oncotarget</i> , 2017, 8, 79546-79555.	1.8	21

#	ARTICLE	IF	CITATIONS
19	Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers. <i>PLoS ONE</i> , 2015, 10, e0137885.	2.5	20
20	Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 685-695.	2.3	20
21	Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. <i>Npj Breast Cancer</i> , 2018, 4, 19.	5.2	19
22	Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. <i>BMC Cancer</i> , 2015, 15, 763.	2.6	18
23	Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. <i>Cancer Research and Treatment</i> , 2018, 50, 175-182.	3.0	18
24	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). <i>Breast Cancer Research and Treatment</i> , 2015, 152, 77-85.	2.5	17
25	Characteristics of metastatic brachial plexopathy in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 1913-1918.	2.2	17
26	Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients. <i>Journal of Korean Medical Science</i> , 2004, 19, 397.	2.5	16
27	Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. <i>Breast</i> , 2005, 14, 304-309.	2.2	16
28	Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 1271.	7.1	15
29	The pretreatment erythrocyte sedimentation rate predicts survival outcomes after surgery and adjuvant radiotherapy for extremity soft tissue sarcoma. <i>Radiation Oncology</i> , 2019, 14, 116.	2.7	12
30	Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 3111-3119.	1.1	12
31	Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 2166-2174.	1.5	12
32	Epidermal Growth Factor Receptor (EGFR) Expression in Operable Non-small Cell Lung Carcinoma. <i>Journal of Korean Medical Science</i> , 2004, 19, 529.	2.5	11
33	Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 17466.	3.3	11
34	The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1287-1293.	1.0	11
35	LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS649-TPS649.	1.6	11
36	A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 509-509.	1.6	11

#	ARTICLE	IF	CITATIONS
37	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018, 103, 127-136.	2.8	10
38	A Propensity Score-matched Analysis of Long-term Oncologic Outcomes After Nipple-sparing Versus Conventional Mastectomy for Locally Advanced Breast Cancer. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	10
39	MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting. <i>Pathology Research and Practice</i> , 2014, 210, 494-500.	2.3	9
40	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+ metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). <i>British Journal of Cancer</i> , 2019, 121, 985-990.	6.4	9
41	Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study. <i>Oncotarget</i> , 2018, 9, 3875-3886.	1.8	9
42	Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1373-1381.	3.0	9
43	Oral Doxifluridine Plus Leucovorin in Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 98-102.	1.3	7
44	Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 6267.	3.7	7
45	A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15031.	4.1	6
46	Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Tumor Biology</i> , 2016, 37, 4919-4927.	1.8	6
47	The role of postoperative radiotherapy after primary tumor resection in patients with de novo stage IV breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 495-505.	1.1	6
48	Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. <i>Targeted Oncology</i> , 2020, 15, 485-493.	3.6	6
49	Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13). <i>Cytokine</i> , 2021, 142, 155487.	3.2	6
50	A phase I study of TGF- β 2 inhibitor, vactosertib in combination with imatinib in patients with advanced desmoid tumor (aggressive fibromatosis).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11557-11557.	1.6	6
51	Postoperative Radiotherapy After Limb-sparing Surgery for Soft-tissue Sarcomas of the Distal Extremities. <i>Anticancer Research</i> , 2016, 36, 4825-4832.	1.1	6
52	A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 406-415.	3.0	6
53	Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG) Tj ETQq1 1 0.784314 5 r gBT /Overl	9.2	5
54	Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. <i>European Journal of Cancer</i> , 2021, 144, 341-350.	2.8	5

#	ARTICLE	IF	CITATIONS
55	Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2 -negative metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 917-924.	5.1	5
56	Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 469-477.	3.0	5
57	Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor. <i>Cancer Research and Treatment</i> , 2014, 46, 339-347.	3.0	5
58	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. <i>Cancer Research</i> , 2022, 82, GS1-01-GS1-01.	0.9	5
59	Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 3225-3234.	7.0	5
60	Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 339-347.	2.3	4
61	Clinical outcomes of angiosarcoma: a single institution experience. <i>Cancer Communications</i> , 2019, 39, 1-4.	9.2	4
62	Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. <i>Journal of Breast Cancer</i> , 2021, 24, 359.	1.9	4
63	Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110619.	3.2	4
64	CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience. <i>Journal of Breast Cancer</i> , 2022, 25, 49.	1.9	4
65	Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study. <i>Cancer Research and Treatment</i> , 2022, 54, 1240-1255.	3.0	4
66	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 10510.	3.3	3
67	Clinical Value of Cyclooxygenase-2 Expression in Human Breast Carcinoma. <i>Cancer Research and Treatment</i> , 2004, 36, 192.	3.0	3
68	Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. <i>Scientific Reports</i> , 2022, 12, 7858.	3.3	3
69	A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy. <i>Investigational New Drugs</i> , 2020, 38, 866-873.	2.6	2
70	Bilateral Extraocular Muscle Metastasis of Nasal Rhabdomyosarcoma Mimicking a Thyroid Associated Orbitopathy: A Case Report. <i>Journal of the Korean Society of Magnetic Resonance in Medicine</i> , 2011, 15, 176.	0.1	2
71	How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers. <i>Journal of Cancer Education</i> , 2020, 35, 545-556.	1.3	1
72	Is asymptomatic surveillance beneficial after standard treatment? A 10-year survival analysis of recurrent BC patients by detection method of recurrence. <i>Breast Journal</i> , 2020, 26, 556-559.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. <i>Anticancer Research</i> , 2020, 40, 5883-5893.	1.1	1
74	The Role and Clinical Effectiveness of Multiline Chemotherapy in Advanced Desmoplastic Small Round Cell Tumor. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492098710.	1.3	1
75	Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11516-11516.	1.6	1
76	Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: A subanalysis of REACT.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15064-e15064.	1.6	1
77	Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Korea—A Sarcoma-Specific, Institutional Registry-Based Analysis. <i>Cancer Management and Research</i> , 2021, Volume 13, 8795-8802.	1.9	1
78	The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study. <i>Cancer Medicine</i> , 2022, 11, 705-714.	2.8	1
79	Quality of life on TSUâ€68: Combination of docetaxel and TSUâ€68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 365-371.	1.1	0
80	<i>FcrR3A</i>-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. <i>Journal of Breast Cancer</i> , 2018, 21, 45.	1.9	0
81	Undervaluation of Radiotherapy for Gross Desmoid Tumors: The Need for Absolute Volume Assessment. <i>In Vivo</i> , 2021, 35, 1777-1784.	1.3	0
82	Abstract PS13-07: Neoadjuvant adriamycin plus cyclophosphamide followed by docetaxel (AC4-D4) vs 5-fluorouracil, epirubicin plus cyclophosphamide followed by docetaxel (FEC3-D3) in stage II or III operable breast cancer : Randomized phase III neo-shorter trial (NCT02001506). , 2021, , .		0
83	Predictive factors of no response during neoadjuvant chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11508-e11508.	1.6	0
84	Changes of pulmonary function test and development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.. <i>Journal of Clinical Oncology</i> , 2014, 32, 530-530.	1.6	0
85	Active surveillance as a treatment option for metastatic or recurrent renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 426-426.	1.6	0
86	Prognostic biomarker exploration for patients with metastatic renal cell carcinoma receiving VEGFR TKI.. <i>Journal of Clinical Oncology</i> , 2015, 33, 491-491.	1.6	0
87	Clinical outcome of patients with metastatic renal cell carcinoma who interrupted VEGFR-TKI after achieving stable disease or better response.. <i>Journal of Clinical Oncology</i> , 2015, 33, 459-459.	1.6	0
88	Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11010-11010.	1.6	0
89	Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 499-507.	3.0	0
90	Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10117-10117.	1.6	0